Mass Spectrometry Based Immunopeptidomics for the Discovery of Cancer Neoantigens.

Details

Serval ID
serval:BIB_CED5BE78B134
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Mass Spectrometry Based Immunopeptidomics for the Discovery of Cancer Neoantigens.
Journal
Methods in molecular biology
Author(s)
Bassani-Sternberg M.
ISSN
1940-6029 (Electronic)
ISSN-L
1064-3745
Publication state
Published
Issued date
2018
Peer-reviewed
Oui
Volume
1719
Pages
209-221
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Abstract
Recent data indicate that endogenous mutated cancer proteins can be processed and presented as HLA binding peptides, leading to their recognition in vivo as "non-self." Targeting such neoantigens would enable immune cells to distinguish between normal and cancerous cells, avoiding the risk of autoimmunity. So far, discovery of such neoantigens relies mainly on prediction-based interrogation of the "mutanome" using genomic information as input, followed by highly laborious and time-consuming T cell screening assays. Currently, mass spectrometry is the only unbiased methodology to comprehensively interrogate the naturally presented repertoire of HLA binding peptides, including peptides derived from tumor-associated antigens and post-translational modified peptides. This chapter describes a detailed protocol for in-depth and accurate mass spectrometry based immunopeptidomics, enabling the direct identification of tissue-derived neoantigens extracted from human tumors.
Keywords
Antigens, Neoplasm/analysis, Antigens, Neoplasm/immunology, Antigens, Neoplasm/metabolism, Chromatography, Affinity/methods, Histocompatibility Antigens Class I/analysis, Histocompatibility Antigens Class I/immunology, Histocompatibility Antigens Class I/metabolism, Histocompatibility Antigens Class II/analysis, Histocompatibility Antigens Class II/immunology, Histocompatibility Antigens Class II/metabolism, Humans, Mass Spectrometry/methods, Neoplasms/immunology, Neoplasms/metabolism, Peptide Fragments/analysis, Peptide Fragments/immunology, Peptide Fragments/metabolism, Cancer immunotherapy, HLA binding peptides, Immunoaffinity purification, Immunopeptidomics, Mass spectrometry, Neoantigens
Pubmed
Create date
08/03/2018 17:36
Last modification date
20/08/2019 15:49
Usage data